Compare DexCom, Inc. (DXCM) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs US Bancorp — how do they compare? DexCom, Inc. trades at $84.46 (market cap $31.81B), while US Bancorp trades at $57.3 (market cap $87.52B). The key difference: US Bancorp is far larger — about 2.8× DexCom, Inc.'s market cap, and US Bancorp pays a 3.85% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and US Bancorp for 97 Days on average.
| DXCM | USB | |
|---|---|---|
Market Cap | $31.81B | $87.52B |
Volume | 2,861,821 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $92.34 | $65.42 |
52-Week Low | $54.84 | $45.28 |
Typical Hold Time | 62 Days | 97 Days |
Enterprise Value | $31.26B | $117.01B |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
U.S. Bancorp (USB) trades at $57.03, down 0.45% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.35 exceeding expectations by 5.5%. Revenue growth accelerated to $28.54B in 2025 with net income margin improving to 27.61%. Analyst consensus remains positive with 51% buy ratings and $69.94 price target representing 23% upside potential.
USB presents a value opportunity with attractive valuation multiples (P/E 11.21, P/B 1.44) and dividend yield of 3.8%. Near-term risks include technical weakness and regulatory uncertainties, but strong fee revenue growth and capital markets performance support the bullish fundamental case. The stock offers income appeal with sustainable dividend growth and clean loan portfolio positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
